AP2A2

Across TCGA pan-cancer cohorts, AP2A2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AP2A2 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AP2A2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AP2A2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, UCEC, and LSCC are the cancer types where AP2A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.890	0.592	.008	30	view →
UCEC	OS	Median	II,III,IV	0.620	1.000	.011	12	view →
LSCC	OS	Quartile	All	0.771	1.000	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

AP2A2–LUAD (OS)

Open the LUAD breakdown →